Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
Trending Stocks Today: Remark Holdings Gets a 11.2% Boost Post-Market
January 30th - US stocks trending post-market.Gainers: $Remark Holdings(MARK.US)$ gets a 11.2% boost to $1.39 with a turnover of $21.4 million. $Skyworks Solutions(SWKS.US)$ up 3.51% to $108 with a tu
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE:TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties' collaboration agreement with Theravance Biopharma Inc (NASDAQ:TBPH).
Astellas Pharma, Eisai, Daiichi Sankyo and Takeda Join Hands to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
Finch Therapeutics Group Inc (NASDAQ:FNCH) will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Ltd (NYSE:TAK). Fo
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) met its primary endpoint
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.The data de
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
Takeda Pharmaceutical Company Limited (NYSE:TAK) reported a fiscal 2021 core net profit of ¥663.7 billion, an increase of 1.3% from the prior year. Core earnings per share reached ¥425, up 1.2%.FY21 n
Takeda Pharmaceutical GAAP EPS of ¥425.00, revenue of ¥3.42T
Takeda Pharmaceutical press release (NYSE:TAK): FY GAAP EPS of ¥425.00.Revenue of ¥3.42T (+7.4% Y/Y).
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
Takeda Pharmaceutical Co Ltd (NYSE:TAK) shared new analyses of Livtencity (maribavir), including additional analyses from Phase 3 SOLSTICE trial data, which supported the FDA approval of Livtencity.Li
Takeda's Takhzyro meets goals of phase 3 trial in children ages 2 to
Takeda (NYSE:TAK) said a phase 3 study of Takhzyro for preventing hereditary angioedema (HAE) attacks in children ages two years to <12 years, met its goals. Takhzyro is approved for preventing re
Do Analysts Agree Wednesday on Takeda Pharmaceutical Co Ltd (TAK) Stock's Target Price?
InvestorsObserver is giving Takeda Pharmaceutical Co Ltd (TAK) an Analyst Rating Rank of 4, meaning TAK is ranked higher by analysts than 4% of stocks. The average price target for TAK is $17.933 and analyst’s rate the stock as a Hold.
Takeda Pharmaceutical Co Ltd (TAK) has fallen -4.43% in a Week, Should You Hold?
A rating of 72 puts Takeda Pharmaceutical Co Ltd (TAK) near the top of the Drug Manufacturers - Specialty & Generic industry according to InvestorsObserver
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID-19 in lab experiments.Icatibant bloc
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
Roche Holdings AG (OTC:RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ:AZN), centering around the latter's newly acquired rare disease drug Ultomiris for
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
Takeda Pharmaceutical Co Ltd (NYSE:TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four programs. The collaboration entails deploying C
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel). The st
Is Takeda Pharmaceutical Co Ltd (TAK) Stock Worth a Buy Thursday?
Takeda Pharmaceutical Co Ltd (TAK) stock is down -13.86% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserver’s proprietary ranking system, gives TAK stock a score of 28 out of a possible 100. That rank
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in Type 3 von Willebr
No Data